Every year, our scientists and patient advisory group identify the studies and topics creating the most impact for people living with arthritis.
Uncover Our Focus for 2026Ongoing and completed studies across our full research portfolio, from prevention and treatment to care and health systems.
Explore Our ResearchMeet the scientists, clinicians, trainees, and patient advisory board members, driving discoveries
Meet Our TeamPeople living with arthritis guide our research priorities, shape study design, and ensure our work reflects real life.
Support Arthritis Research Canada with your time and skills. Whether you want to help at an event or host your own, there is a place for you here.
Living with arthritis? Explore open studies looking for participants and help shape the future of arthritis care.
Scientific Study Title:
Start Date:
End Date:
Research Category
Tags
Life-changing arthritis research is only possible with your help!
Reason For Research
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, and internal organs. A rare, but serious complication of scleroderma is sudden kidney failure (scleroderma renal crisis). One-third of patients with kidney failure will die within one year. Among those who survive, one-quarter will remain on dialysis (treatment for kidney failure) after one year. (Hudson et al., Seminars Arthritis Rheumatol. 2014).
At present, there is no standardized set of criteria to define scleroderma renal crisis; instead, there are 41 different published sets of criteria (Hoa et al., Autoimmunity Rev. 2017). Not having a common standard has slowed research on this condition, leading to a poor understanding of the problem and a lack of more effective treatments.
The Scleroderma Clinical Trials Consortium is the leading international group that advances standards of research for people with scleroderma. In 2015, they asked us to develop classification criteria for scleroderma renal crisis. The goal is to improve future studies looking at new treatments for scleroderma renal crisis. Since then, we have asked experts to identify a set of items that could be included in the classification criteria (Butler et al. Arthritis Rheumatol. 2019) and we have collected the data for this core set of items from an international group of scleroderma patients with new onset scleroderma renal crisis (our ‘inception cohort’).
Execution of Research
We are starting the next phase of this project using the data from the core set and the 1000Minds methodology. We will ask a panel of experts to rank cases according to whether the case would be classified as scleroderma renal crisis. Our research team members are world experts when developing classification criteria using this methodology. The research team has also helped create new classification criteria for lupus and antiphospholipid syndrome. We are confident that this new classification criteria for scleroderma renal crisis will become the standard used for all future research and will lead to improved outcomes for people with scleroderma who develop renal crisis.
Involvement
The cohort group that was initiated in 2015 includes Scleroderma patients who developed scleroderma renal crisis. A patient partner will participate on the 1000Minds panel. The Research Team is composed of accomplished researchers leading the fields of scleroderma, scleroderma renal crisis and classification criteria for rheumatic diseases.